There are a few studies on the treatment of sporotrichosis. The standard drug used is itraconazole. However, the use of itraconazole is limited by its interaction with other drugs.ObjectiveTo evaluate the effectiveness and safety of 250 mg terbinafine for the treatment of cutaneous sporotrichosisin patients in whom itraconazole use is not possible.MethodsWe performed a descriptive study of cutaneous sporotrichosis cases treated with 250 mg terbinafine for whichitraconazole was contraindicated or resulted in severe or moderate pharmacological interactions. Sporotrichosis wasdiagnosedbasedontheisolationofS. schenckii.ResultsFifty patients seen between July 2005 and September 2007 were included. Forty-five (92%) patients reportedcontact with a sick cat and 47 (94%) presented comorbidities (high blood pressure: 64.0%; diabetes mellitus: 30.0%;dyslipidemia: 16.7%; depression: 10.0%; migraine: 2.1%; Parkinsonı ́s disease: 2.1%; peptic ulcer disease: 2.1%; heartfailure: 2.1%, and arrhythmia: 2.1%). All patients used some medication interacting with itraconazole (psycholeptics:36.0%; antidiabetic agents: 28.0%; hypolipemiant agents: 18.0%; calcium-channel blockers: 16.0%; anticonvulsants:8.0%; cardiotropic drugs: 6.3%; antacids: 6.3%, and antiparkinsonian agent: 2.1%). Most patients (96%) were curedwithin a mean period of 14 weeks. The drug was discontinued due to a skin rash in one patient. There were no cases ofrecurrence of the mycosis within a mean follow-up period of 37 weeks.ConclusionsThis study suggests that 250 mg/day terbinafine is an effective and well-tolerated alternative to drugtherapy of cutaneous sporotrichosis in a population in which itraconazole use is not possible.